Future possibilities in the prevention of breast cancer: Intervention strategies in BRCA1 and BRCA2 mutation carriers

被引:0
作者
Rosalind A Eeles
机构
[1] Institute of Cancer Research and Royal Marsden NHS Trust,Clinical Senior Lecturer and Honorary Consultant in Cancer Genetics and Clinical Oncology
来源
Breast Cancer Research | / 2卷
关键词
BRCA1; BRCA2; interventions; management; mutation carriers;
D O I
暂无
中图分类号
学科分类号
摘要
The development of intervention strategies for carriers of mutations in the BRCA1 and BRCA2 genes has several considerations. The first are primary prevention and secondary prevention in unaffected carriers using medical/surgical or lifestyle strategies to prevent cancer development, or screening methods to detect cancers at an earlier stage. The options available are determined by the magnitude and age at onset, risk profile of cancer in carriers (the penetrance function of the gene) and the different cancer sites involved. The management of affected individuals who are BRCA1 and BRCA2 mutation carriers may be altered by their carrier status, because the tumour histology, efficacy of treatment and risk of subsequent cancer development is determined by the BRCA1 and BRCA2 germline status. Carriers of BRCA1 and BRCA2 mutations are relatively rare, so the strategies for management should be determined by international multicentre studies.
引用
收藏
相关论文
共 207 条
[1]  
Easton D(1990)The contribution of inherited predisposition to cancer incidence. Cancer Surveys 9 395-416
[2]  
Peto J(1991)Genetic analysis of breast cancer in the Cancer and Steroid Hormone study. Am J Hum Genet 48 232-242
[3]  
Claus EB(1995)Breast and ovarian cancer incidence in Am J Hum Genet 56 265-271
[4]  
Risch N(1994)1 carriers. Science 266 66-71
[5]  
Thompson WD(1995)A strong candidate for the breast and ovarian cancer susceptibility gene, Nature 378 789-791
[6]  
Easton DF(1995)1. Am J Hum Genet 57 1457-1462
[7]  
Ford D(1998)Identification of a breast cancer gene, Am J Hum Genet 62 676-689
[8]  
Bishop DT(1994)2. Lancet 343 692-695
[9]  
and the Breast Cancer Linkage Consortium Y(1996)Estimates of the gene frequency of Nature Genet 13 120-122
[10]  
Miki J(1999)-1 and its contribution to breast and ovarian cancer incidence. J Natl Cancer Inst 91 1310-1316